“…Both radiobiological results are in good agreement with a complementary experiment performed at the Munich Tandem Van-de-Graaf accelerator [37,38] and a recent study of the RBE of intense single pulses of LDPR, where the dose applied to the cells was varying across the probe and analyzed retrospectively for individual irradiated areas [26]. Making use of different pulse modes of the Tandem accelerator, the first study focused on the dependence of the RBE on the peak dose rate by comparing the effect of short-pulses (few nanoseconds) and continuous beams of 20 MeV protons, while the latter directly made use of the intrinsically high peak dose rates of LDPR of up to few Gy per pulse.…”
Proton beams are a promising tool for the improvement of radiotherapy of cancer, and compact laserdriven proton radiation (LDPR) is discussed as an alternative to established large-scale technology facilitating wider clinical use. Yet, clinical use of LDPR requires substantial development in reliable beam generation and transport, but also in dosimetric protocols as well as validation in radiobiological studies. Here, we present the first dose-controlled direct comparison of the radiobiological effectiveness of intense proton pulses from a laser-driven accelerator with conventionally generated continuous proton beams, demonstrating a first milestone in translational research. Controlled dose delivery, precisely online and offline monitored for each out of *4,000 pulses, resulted in an unprecedented relative dose uncertainty of below 10 %, using approaches scalable to the next translational step toward radiotherapy application.
“…Both radiobiological results are in good agreement with a complementary experiment performed at the Munich Tandem Van-de-Graaf accelerator [37,38] and a recent study of the RBE of intense single pulses of LDPR, where the dose applied to the cells was varying across the probe and analyzed retrospectively for individual irradiated areas [26]. Making use of different pulse modes of the Tandem accelerator, the first study focused on the dependence of the RBE on the peak dose rate by comparing the effect of short-pulses (few nanoseconds) and continuous beams of 20 MeV protons, while the latter directly made use of the intrinsically high peak dose rates of LDPR of up to few Gy per pulse.…”
Proton beams are a promising tool for the improvement of radiotherapy of cancer, and compact laserdriven proton radiation (LDPR) is discussed as an alternative to established large-scale technology facilitating wider clinical use. Yet, clinical use of LDPR requires substantial development in reliable beam generation and transport, but also in dosimetric protocols as well as validation in radiobiological studies. Here, we present the first dose-controlled direct comparison of the radiobiological effectiveness of intense proton pulses from a laser-driven accelerator with conventionally generated continuous proton beams, demonstrating a first milestone in translational research. Controlled dose delivery, precisely online and offline monitored for each out of *4,000 pulses, resulted in an unprecedented relative dose uncertainty of below 10 %, using approaches scalable to the next translational step toward radiotherapy application.
“…With respect to these endpoints no indication for a significantly altered efficiency of pulsed protons compared to a continuous irradiation was observed (8)(9)(10)(11). Further biological experiments were performed using a human skin tissue model to account for the 3D geometry and the cell interaction, again without statistically significant changes in RBE according to dose rate (12).…”
“…At the moment such a simulation at high energies would be too speculative as the input parameters are not known. In the meantime, radiobiological experiments [27][28][29][30] will continue to complement these developments to evaluate the potential of laser-driven particle beams with respect to their biological effects. Overall, this concept is an interesting application of lasers in medicine which needs further investigation but may offer a unique tool for cancer therapy.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.